Welcome to our dedicated page for Cvrx news (Ticker: CVRX), a resource for investors and traders seeking the latest updates and insights on Cvrx stock.
CVRx, Inc. develops, manufactures and commercializes neuromodulation medical devices for cardiovascular disease. Its Barostim therapy is an implantable system that delivers electrical pulses to carotid baroreceptors to rebalance autonomic nervous system signaling and improve symptoms in heart failure patients.
Company updates commonly cover Barostim commercialization in the United States and Europe, FDA approval and Breakthrough Device history, CE Mark status for heart failure and resistant hypertension in the European Economic Area, clinical data from heart failure studies, reimbursement and coding developments, quarterly operating results, financing activity and board governance matters.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.